HPV infection - Screening, diagnosis and management of HPV-induced lesions

Reference
1 Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. Hum Vaccin Immmunother 2019; 15 (01) 146-55
2 Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol 2017; 40 (02) 80-5
3 Gultekin M, Karaca MZ, Kucukyildiz I, Dundar S, Keskinkilic B, Turkyilmaz M. Mega HPV laboratories for cervical cancer control: challenges and recommendations from a case study of Turkey. Papillomavirus Res. 2019; 7: 118-22
4 Ministério da Saúde. Instituto Nacional de Câncer. Tipos de câncer: câncer do colo do útero [Internet]. 2020 [cited 2020 Oct 15]. Available from: https://www.inca.gov.br/tipos-de-cancer/cancer-do-colo-do-utero
5 Possati-Resende JC, Vazquez FL, Pantano NP, Fregnani JHTG, Mauad EC, Longatto-Filho A. Implementation of a cervical cancer screening strategy using HPV self-sampling for women living in rural areas. Acta Cytol. 2019; 64 (1-2) 7-15
6 Jansen EEL, Zielonke N, Gini A, Anttila A, Segnan N, Vokó Z. et al. Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review. Eur J Cancer 2020; 127: 207-23
7 Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Diretrizes brasileiras para rastreamento do câncer do colo do útero [Internet]. 2a ed.. Rio de Janeiro: INCA; 2016. [cited 2019 Nov 18] Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//diretrizesparaorastreamentodocancerdocolodoutero_2016_corrigido.pdf
8 Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A. et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020; 70 (05) 321-46
9 Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical cancer screening Programs in Europe: The transition towards HPV vaccination and population-based HPV testing. Viruses 2018; 10 (12) 729
10 Zeferino LC, Bastos JB, Vale DBAP, Zanine RM, Furtado de Melo YLM, Pereira Primo WQS. et al. Guidelines for HPV-DNA testing for cervical cancer screening in Brazil. Rev Bras Ginecol Obstet. 2018; 40 (06) 360-8
11 Speck NMG, Carvalho JP. Dossiê de estratégias do rastreamento do câncer de colo uterino no Brasil. São Paulo: FEBRASGO; 2018. [cited 2019 Dec 15]. Available from: https://www.febrasgo.org.br/pt/noticias/item/download/167_d8aac29103a80d079e7031cf127c72d6#:∼:text = Baseado%20em%20revis%C3%A3o%20extensa%20de,o%20rastreamento%20baseado%20em%20citologia
12 Federação Brasileira das Associações de Ginecologia e Obstetrícia (FEBRASGO). Rastreamento do câncer de colo útero no Brasil [Internet]. 2019 [cited 2020 Dec 15]. Available from: https://www.febrasgo.org.br/pt/noticias/item/551-rastreamento-do-cancer-de-colo-uterino-no-brasil?highlight=WyJkb3NzaWUiXQ = =
13 Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Protocolo clínico e diretrizes terapêuticas para atenção integral às pessoas com Infecções Sexualmente Transmissíveis (IST). Brasília (DF): Ministério da Saúde; 2020
14 Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines [Internet]. 2015 [cited 2019 Oct 10]. Available from: https://www.cdc.gov/std/tg2015/default.htm
15 Grillo-Ardila CF, Angel-Muller E, Salazar-Díaz LC, Gaitán HG, Ruiz-Parra AI, Lethaby A. Imiquimod for anogenital warts in non-immunocompromised adults. Cochrane Database Syst Rev. 2014; (11) CD010389
16 Speck NMG, Ribalta JCL, Focchi J, Costa RRL, Kesselring F, Freitas VG. Low-dose 5-fluoruracil adjuvant in laser therapy for HPV lesions in immunosuppressed patients and cases of difficult control. Eur J Gynaecol Oncol. 2004; 25 (05) 597-9
17 Meijer CJ, van den Brule AJ, Snijders PJ, Helmerhorst T, Kenemans P, Walboomers JM. Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. IARC Sci Publ. 1992; (119) 271-81
18 Mitchell MF, Hittelman WN, Hong WK, Lotan R, Schottenfeld D. The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. Cancer Epidemiol Biomarkers Prev. 1994; 3 (07) 619-26
19 Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999; 91 (03) 252-8
20 Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F. et al. ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020; 24 (02) 102-31
21 Rufail M, Lew M, Pang J, Jing X, Heider A, Cantley RL. Low-grade squamous intraepithelial lesion on Papanicolaou test: follow-up rates and stratification of risk for high-grade squamous intraepithelial lesion. J Am Soc Cytopathol. 2020; 9 (04) 258-65
22 Queiroz Filho J, Freitas JOC, Pessoa DC, Eleutério Júnior J, Giraldo PC, Gonçalves AK. Assessment of 100% rapid review as an effective tool for internal quality control in cytopathological services. Acta Cytol. 2017; 61 (03) 207-13
23 Federação Brasileira das Associações de Ginecologia e Obstetrícia. Rastreio, diagnóstico e tratamento do câncer de colo de útero. São Paulo: FEBRASGO; 2017
24 Wong OGW, Tsun OKL, Tsui EY, Chow JNK, Ip PPC, Cheung ANY. HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening population-Cobas and Aptima HPV tests. J Clin Virol. 2018; 109: 13-8
25 ASCUS-LSIL Traige Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003; 188 (06) 1393-400
26 Massad LS, Collins YC, Meyer PM. Biopsy correlates of abnormal cervical cytology classified using the Bethesda System. Gynecol Oncol. 2001; 82 (03) 516-22
27 Ministério da Saúde. Departamento de Informática do SUS (Datasus). Sistema de Informação do Câncer do Colo do Útero (SISCOLO) [Internet]. 2013 [cited 2018 Aug 13]. Available from: http://w3.datasus.gov.br/siscam/index.php
28 Castle PE, Adcock R, Cuzick J, Wentzensen N, Torrez-Martinez NE, Torres SM. et al. Relationships of p16 immunohistochemistry and other biomarkers with diagnoses of cervical abnormalities: implications for LAST terminology. Arch Pathol Lab Med. 2020; 144 (06) 725-34
29 Chen JY, Wang ZL, Wang ZY, Yang XS. The risk factors of residual lesions and recurrence of the high-grade of cervical intraepithelial lesions (HSIL) patients with positive-margin after conization. Medicine (Baltimore) 2018; 97 (041) e12792
30 Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA. et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020; 395 (10224): 575-90